Member Info for Dartron

If you follow them on Twitter, they are putting articles out regularly, or even Linked In.

Off topic, but I have also found that to be the case for Shearwater (SWG) and Corero networks (CNS). I guess AIM is too good to give up if the business fails, just pick another one. sst1, Cheers for a more joined up explanation. Yes I spotted a lot of Jewish related RNS, thought it was a coincidence.

Cheers guys

Honestly think it was being shorted. I took some more at 256, seems a good entry level, back to the 50 day and 100 day averages - and also a prior key level which should start to act as support. Might go lower, you never know, but its been dropping 2 weeks now, hopefully returns are diminishing for shorters as the price gets more of a buy opportunity.

It has also sat on the 100ma, which I think serves as a good retracement.
What is encouraging me today is that there seems to be some large buys all at the high of the day.
I know this site is reporting everything as a sell, but that is because the ask is being used to hide buying.
It would be awesome if that was the company buying back shares, I wont get my hopes up though.
As you said, a further consolidation around 30p would be a good outcome.

If you are talking longer term, I am comforted that the options are excised at 24p. If you cant wait 3 years, I think they will ramp this up somehow so that there is a large profit in Exercising those options. In a 3 year perspective, your buying in at the bottom. This is why I would like to see those buy backs resume.

Radium, I dont really care to argue or defend Totally PLC, but the google chart did get my curiosity. I had no idea Totally was that old. I did some digging and it seems Totally were a digital publisher up to 2011. It seems their foray into anything health related was a publishing contract in 2011.
https://www.lse.co.uk/rns/TLY/nhs-contract-win-53c73kflkiz9uaf.html
Prior to 2011, the share price had been as high as £5.00, but since embarking on health care it looks like the highest price has been briefly £1.60. No idea what the market cap would have been at that time, but since then I see plenty of placings and warrants so the share price is a little misleading. Had you bought in 2019 at 9p you could have 5 bagged up to 45p in 2022, so again the comparison is a little misleading. It doesnt matter what this company was doing 10 years ago IMO - changing direction is not uncommon with some of these AIM stocks. Sometimes entering after 10 years, once all the funding is done and dilution, you walk away with the functioning company at a good price.
Yes this is a slow growing stock, with risks attached. Its not for everyone, but the earnings are growing and I think that is what is catching peoples eye here. Totally isnt my best stock, or my favorite by any means, but I think on the facts alone its not time to sell. I shall wait and see what the next move is from the company, could work out worse, or better. Who knows. I take no pleasure in hearing of any investing loss, we have all had them, probably even you. The answer to your previous question was "yes". I thought that was clear.

The interims show that the company is profitable and funded.
· Group turnover up 14.1% to £70.3 million (H1 2022: £61.6 million)
· Gross profit up 2.6% to £11.9 million (H1 2022: £11.6 million)
· Increase in EBITDA profit to £3.4 million (H1 2022: £3.3 million)
· Profit before tax of £1.0 million (H1 2022: £0.9 million)
· Cash position of £7.4 million at 30 September 2022
Plenty of II support too, most likely at higher prices.
Mcap currently 56M.

Thanks SeaTank that is a much more balanced post. Interesting what you write. I will keep watching.

I dont think anyone here needs to change your mind Radium, if that is what you think then great. I do think the share sale was a plausible coincidence. I expect online journalism takes a few hours to knock up and stick online, especially that factually sp**** P.O.S. The share sale would likely have been organised at least a day or so in advance, since it was in a benefit scheme, and would need to go off to brokers for the sale. On what date should you use the share price to calculate your tax liability? I don't think these things are done on a whim. Perhaps it would have been more beneficial to settle a lower tax bill on the revised value of the shares after the article? Maybe they feel robbed?!

If there is any skulduggery, I think the journalist should have been short, or now be loading up. He has effectively manipulate the price on a nonsense storey. As was said, HSJ have form for printing rubbish about this PLC. Maybe that is how he settles his tax bill!

It would have been great if the BOD used cash to settle the tax liability and held the shares, but I imagine a financial advisor would advise they do exactly as they did (play it safe). If they are smart, maybe they will now buy. It would show a lot of support, although people like you will cry unfair play so they are dammed either way.

Agree, good call Nutmeg. I may have to cut and run before I give too much back.

Can you provide an average for Bill, if you assign nill value to any free shares that he got. So we know just what this owes him. This would serve as a lower bound price. Sorry, new to this share, but great work Lionheart.

The RNS feed does not work for PAF. Although no RNS has been issued since 9th Dec. Nothing about what you are discussing.

On the plus side, they have stood still, rather than gone backwards, with revenue similar to 2021. Corero has 70 employees worldwide, I think the issue is that the admin costs, especially the development costs, make this company un profitable, hence why no takeover acquisitions. They had $5M cash from TU, so I expect this to have reduced in the next update. If that is the case, its just existing off placings. Are they going to manage to keep abreast of cyber developments with no R&D budget? How has the recent new hires to increase sales worked, with revenue down?

Jan 2022:
Tanya will be based in the US and will be responsible for managing Corero's global sales function including the further development of Corero's go-to-market strategy, as well as the management of key strategic accounts and the Company's indirect channel.

I like the company and the management, but unfortunately, this is similar to other tech companies that are excellent, but not profitable - BIRD springs to mind. I dont think I would buy back at any price, as I dont see a profit here.

Looking at the interims up to 30th September 2022, Totally had been awarded extensions to 15 of these UC's in the past 6 months. I think reputationally there isnt much to worry about. The same division has been awarded a 10M contract per anum on the 16th Jan, if there was a problem, I doubt they would have got this?
I also think the impact to revenue is minimal, adding up the other revenues reported in the last interims. Note that the company has decided to pay almost £1M out as a dividend in a few days time, again hardly feels like they have money worries. Finally, to turn your own argument upside down if the margins are so thin, they haven't lost much? If they had staff issues, they now have spare? etc etc.

From Septembers interims:

Awarded extensions to 15 existing urgent care contracts amounting to c.£37 million in value, underpinning recurring income and reflecting the quality of service and strength of relationships with NHS partners

Step in contract awarded for the provision of NHS 111 services in Devon valued at up to £850,000, which has been extended until January 2023 for an additional contract value of up to £700,000

· Five-year contract extension awarded to Energy Fitness Professionals for the management of gyms across 34 sites for the Royal Mail, worth c.£2.5 million and extending the existing 18-year relationship to provide additional services

· One new contract and four contract extensions, collectively valued at approximately c.£9.5 million, awarded to Pioneer Healthcare to support the reduction of NHS waiting lists across multiple specialities

Post interims, the same UC division has been awarded a 10M contract:
Totally's Urgent Care division awarded new contract worth c.£10m p.a. to provide national contingency support for NHS 111, £10 million per annum, initially for one year with the option to extend for a further year.

I think it is just a formality cancelling the contract, making sure the paper trail is correct if they are no longer going to work for that client. It may also increase pressure on the IC's to find a new provider, of which Totally has put in a tender. Seems the PR side of this has gone badly, but I am undecided if the commercials have gone as badly as has been suggested. If they are still in tender, they are unable to say too much. We already know that the HSJ article is incorrect and misleading at best, based on 'sources' not facts. The article can not be correct if Totally have cancelled the contract, this is complete contradiction to the article, and also a motivation for Totally to do that and then RNS (in other words show the article as rubbish).

"Greenbrook has previously submitted a tender to deliver services at the four UTCs from 31 January 2023 onwards and continues to await the result of that procurement process."

If this gets renewed, and the share price pops back to 36p, some people may regret selling. I added today and will be holding until we get a trading update to understand how this affects me as an investor, not a health service user.

Calm down, calm down. Its only a spread bet. You wont drive it lower now sonny. Time to get back in to boil. Bye.

Bit confused..
The HSJ article say it has been terminated, but if you read the original bid proposal, it was always up to 31st January 2023. This is the link from the original article regarding the bid, https://bidstats.uk/tenders/2022/W27/778108961
This is also in keeping with todays RNS, if read carefully, the contract has just run to its end.

This might explain why there has been more buys at 30p than sells.

Not great the timing of the director share sales, but I for one wont be deprived of my shares for a 10% loss.

https://www.fool.co.uk/2023/01/19/aim-shares-4-growth-stocks-id-buy-to-hold-for-10-years/

TLY is their pick. I also put ANCR on my watch list.

Berenberg raises Pan African Resource price target to 32 (27) pence - 'buy' (23/01/2023)

Reported operating loss of £(3.9)m (H1 2022: operating profit of £1.3m)
Reported loss before tax on continuing operations of £(4.3)m (H1 2022: profit before tax of £0.9m)
Basic loss per share from continuing operations of (4.2)p (H1 2022: earnings per share of 0.7p)
Net debt1 as at 30 September 2022 of £14.1m (31 March 2022: £10.1m)

Sorry but this does not look like earnings accreditive to me or fundamentally cash generative (at the moment). It is valid to be concerned that the cash position is decreasing. Of co**** those that speak for TPX are going to have a positive spin on this, but the balance sheet tells otherwise. In fact a quick look and it appears TPX has only reported a FY profit once - not much of a track record. Not sure how Seatank can speak for the companies acquisition strategy, even though its pretty obvious with no cash and low EV those options are not available. I still think they may need to raise funds one way or another.

David Beech 18,922,309 22.05%
Octopus Investments 14,023,727 16.34%
Columbia Threadneedle Investments 10,051,432 11.71%
Wasatch Advisors Inc 5,359,090 6.25%
Invesco 3,446,292 4.02%
BGF 3,325,120 3.87%
==========================
Total 47.9%
==========================
29th Jan 2021, David Andrew Beech sold 15,700,000 at 390.00(£58M)
22 Nov 2022, David Andrew Beech Buy 1,185,964 at 83.90 (£1M)
(nice trade!)
==========================
Will he buy more?

Good to see them taking advantage of the price drop today 20/01/23 - 13800 at 71p.